Maker of HIV test gets stock lift OraSure stock surges on government call for routine HIV testing for most Americans. NEW YORK (CNNMoney.com) -- Most Americans should get tested for the virus that causes AIDS, the government said Thursday, giving a lift to the stock of a leading maker of HIV tests. The stock of OraSure Technologies (Charts), the maker of the OraQuick rapid HIV test, surged 21.8 percent after the Centers for Disease Control recommended routine testing for all Americans between the ages of 13 and 64. Previously, the CDC had recommended routine testing only for those considered high-risk for contracting HIV, such as sexually active gay men, users of intravenous drugs like heroin and patients at hospitals in high-risk areas. The CDC had also recommended routine testing for pregnant women. There is no cure for AIDS. HIV, the virus that causes it, can be spread through sexual activity and the use of infected needles, and infected mothers can spread it to their babies through breast milk. The drug makers GlaxoSmithKline (down $0.07 to $53.98, Charts), Merck (up $0.03 to $41.97, Charts), Novartis (up $0.01 to $58.02, Charts), Sanofi-Aventis (up $0.38 to $44.29, Charts), Gilead (down $0.71 to $64.24, Charts) and Wyeth (down $0.28 to $50.61, Charts) are all trying to develop an AIDS vaccine, which is considered the Holy Grail of HIV research. Chembio Diagnostics also makes a rapid diagnostics test for HIV. |
|